- PLATFORM LOGINS
- |
- CONTACT
- Request a Demo
-
NantHealth Founder and CEO to unveil publicly for the first time in 10 years, NantDaVinci, the world’s first whole genomics transcriptomics supercomputing medical reasoning engine covered by over 100 seminal patents advancing immunotherapy as the next generation of cancer care and the potential for cancer vaccines
The presentation, “Unlocking the Code with the NantDaVinci Cancer
Engine” will unveil how
To date, the NantDaVinci Supercomputing Engine has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with multiple tumor types—and with the world's largest database of human cancer whole genomes— has enabled the discovery of novel neoepitopes in cancer tissue for the development of neoepitope antibodies and vaccines in the war against cancer. Over 100 seminal patents have been issued covering this integrated augmented, amplified and adaptive intelligence platform.
The session will also be available for viewing via Facebook Live at www.Facebook.com/NantHealth.
WHAT: |
Unlocking the Code with the NantDaVinci Cancer Engine |
||
WHO: |
|
||
WHEN: |
|
||
WHERE: |
HIMSS Annual Conference & Exhibition | ||
|
|||
|
|||
|
|||
MEDIA |
|||
CONTACT: |
|
||
|
|||
310-853-7802 | |||
Cautionary Note Concerning Forward-Looking Statements
This
press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including, among
others, statements regarding the capabilities and anticipated utility of
our GPS Cancer, including predicting patient response and resistance to
therapeutics, enabling diagnoses by physicians and accelerating efforts
to bring novel combinations of therapeutic agents to cancer patients.
Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results. Factors that may cause future results to
differ materially from management’s current expectations include, among
other things, that GPS Cancer may not perform as anticipated, that
sufficient physicians may not adopt GPS Cancer to assist their diagnoses
or that healthcare payers may not provide reimbursement for GPS Cancer
as expected. Our business is subject to numerous additional risks and
uncertainties, including, among others, risks relating to market
acceptance of our products; our ability to successfully launch new
products and applications; competition; our sales, marketing and
distribution capabilities; our planned sales, marketing, and research
and development activities; unanticipated increases in costs or
expenses; and risks associated with international operations.
Information on these and additional risks, uncertainties, and other
information affecting our business and operating results can be found in
our existing and future filings with the
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20170213005106/en/
jhodson@nantworks.com
Source: